Vanguard Personalized Indexing Management LLC Has $102,000 Position in Amicus Therapeutics, Inc. $FOLD

Vanguard Personalized Indexing Management LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 63.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,887 shares of the biopharmaceutical company’s stock after acquiring an additional 6,932 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Amicus Therapeutics were worth $102,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Strs Ohio acquired a new position in Amicus Therapeutics in the 1st quarter worth about $30,000. PNC Financial Services Group Inc. increased its holdings in Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 3,497 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Amicus Therapeutics in the first quarter worth approximately $53,000. 111 Capital bought a new position in Amicus Therapeutics during the second quarter valued at approximately $77,000. Finally, Bryce Point Capital LLC acquired a new stake in Amicus Therapeutics in the first quarter valued at approximately $100,000.

Wall Street Analyst Weigh In

Several brokerages have recently commented on FOLD. Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Thursday, September 18th. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Wall Street Zen raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amicus Therapeutics in a research report on Friday. Finally, Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $15.88.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $8.67 on Monday. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -72.24 and a beta of 0.56. The business has a 50 day moving average price of $8.02 and a 200 day moving average price of $6.93. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.